Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Large Decline in Short Interest

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a significant decrease in short interest during the month of September. As of September 30th, there was short interest totaling 28,906 shares, a decrease of 51.7% from the September 15th total of 59,859 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average daily volume of 160,909 shares, the short-interest ratio is presently 0.2 days.

Fresenius SE & Co. Stock Up 2.2%

Shares of FSNUY traded up $0.27 during mid-day trading on Friday, reaching $12.74. 213,273 shares of the stock traded hands, compared to its average volume of 171,384. Fresenius SE & Co. has a 12-month low of $10.33 and a 12-month high of $33.93. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.41. The firm has a market cap of $28.70 billion, a price-to-earnings ratio of 16.13 and a beta of 0.60. The stock has a fifty day simple moving average of $13.04 and a 200 day simple moving average of $12.35.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $6.91 billion during the quarter, compared to analyst estimates of $6.65 billion. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.25%. Sell-side analysts expect that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on FSNUY shares. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a research note on Thursday, August 6th. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research note on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating. According to MarketBeat, Fresenius SE & Co. has a consensus rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.